Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4238MR)

This product GTTS-WQ4238MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4238MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13142MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ7876MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ12654MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ13980MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10800MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ4891MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ930MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ11268MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW